Regional Analysis

Global Implantable Drug Delivery Devices – Regional Analysis

North America is expected to hold dominant position in the implantable drug delivery devices market, owing to increasing research and development activities taking place in the region. For instance, in 2019, Merck Sharp & Dohme Corporation initiated a clinical trial (Phase I) for evaluating the safety and efficacy of Islatravir (MK – 8591) implant in patients suffering from HIV – 1 infection. It was concluded in Phase -1 that Ialatravir implant provides protection for more than a year from spreading of HIV.

Furthermore, increasing product launches is expected to boost the global implantable drug delivery devices market growth over the forecast period. For instance, in 2017, Abbott Laboratories launched XIENCE everolimus-eluting coronary stent system, with features like a thinner profile, increased flexibility, longer lengths, and small-diameters. The stent supports the patients suffering from coronary artery disease to regain their health and to lead a healthy lifestyle.

Geographies covered:

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC, Israel and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa